InsidersTradesSigma
Total declarations
Companies
▲ Purchases (10 ops.)
▼ Sales (3 ops.)
Insider track record
ExecutiveDisclosed buys
10
Disclosed sells
3
T+90 hit rate
60%
T+90 mean return
+2.6%
Across 20 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Pauls Matthew, Director. Insider active across 4 companies, notably Pelthos Therapeutics Inc.. Cumulatively, 24 reports have been logged. Breakdown: 10 buys · 3 sells. Total volume traded: €482k. Activity tracked since 21 May 2021. The latest transaction was filed on 2 July 2026 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations24 total
692 shares@ US$25.99590.020% mcap87.5% of flowCommon StockSEC:0001919246-26-000101:0
94 shares@ US$27.36040.0029% mcap12.5% of flowCommon StockSEC:0001919246-26-000101:1
25,478 shares0Common StockSEC:0001919246-26-000042:0
25,478 shares0Common StockSEC:0001919246-26-000042
5,937 shares@ US$4.60100.0% of flowCommon StockSEC:0001415889-25-009298:0
400,000 shares0Common StockSEC:0000950170-24-136782:0
6,500 shares0Common StockSEC:0001415889-24-016310:0
84,000 shares@ US$4.713139.0% of flowCommon StockSEC:0001209191-23-060009:0
109,680 shares@ US$4.4549.1% of flowCommon StockSEC:0001209191-23-058850:0
325,000 shares0Common StockSEC:0001209191-22-061411:0
62,318 shares@ US$1.240.0055% mcap50.4% of flowCommon StockSEC:0001209191-22-000131:0
62,318 shares@ US$1.247.5% of flowCommon StockSEC:0001209191-22-000131
400,000 shares0Common StockSEC:0001209191-21-069586
400,000 shares0Common StockSEC:0001209191-21-069586:0
6,500 shares@ US$1.05990.7% of flowCommon StockSEC:0001209191-21-068494
Ideal exit: 4 Sept 2022 (T+270)
6,500 shares@ US$1.05990.0005% mcap4.5% of flowCommon StockSEC:0001209191-21-068494:0
Ideal exit: 4 Sept 2022 (T+270)
10,000 shares@ US$1.09541.1% of flowCommon StockSEC:0001209191-21-067432
Ideal exit: 29 Aug 2022 (T+270)
10,000 shares@ US$1.09540.0008% mcap7.1% of flowCommon StockSEC:0001209191-21-067432:0
Ideal exit: 29 Aug 2022 (T+270)
10,000 shares@ US$1.100.0008% mcap7.2% of flowCommon StockSEC:0001209191-21-066036:0
Ideal exit: 15 Aug 2022 (T+270)
10,000 shares@ US$1.101.1% of flowCommon StockSEC:0001209191-21-066036
Ideal exit: 15 Aug 2022 (T+270)
15,000 shares@ US$1.181.7% of flowCommon StockSEC:0001209191-21-052200
Ideal exit: 14 May 2022 (T+270)
15,000 shares@ US$1.180.0012% mcap11.2% of flowCommon StockSEC:0001209191-21-052200:0
Ideal exit: 14 May 2022 (T+270)
10,000 shares@ US$1.62980.0011% mcap9.8% of flowCommon StockSEC:0001209191-21-035163:0
Ideal exit: 15 Feb 2022 (T+270)
10,000 shares@ US$1.62989.8% of flowCommon StockSEC:0001209191-21-035163
Ideal exit: 15 Feb 2022 (T+270)
24 of 24 declarations
About Pauls Matthew
Matthew Pauls is a director at Pelthos Therapeutics Inc.
